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LETTERS TO THE EDITOR 
Regarding "Comparison of  endovascular nd 
conventional vascular prostheses in an experimental 
infection model" 
To the Editors: 
With great interest we read the article by Parsons et al. 
(J Vase Surg 1996;24:920-6), which suggested that endo- 
vascular prostheses have a higher rate of infection than 
vascular prostheses implanted in conventional surgery in an 
experimental model. Our clinical and experimental studies 
do not confirm completely their conclusion. 1,2 Therefore, 
we would like to add our experience with endoluminal 
repair of infrarenal aortic aneurysms. 
Since September 1994 we have performed endolumi- 
hal repair for exclusion ofinfrarenal aneurysm with use of a 
polyester textile-covered nitinol stent) ,2 In a series of 83 
patients treated endoluminally, no graft infection oc- 
curred. The mean follow-up period is 18 months, ranging 
from 8 days to 32 months. Our follow-up protocol in- 
cludes clinical examination, intraarterial ngiography, and 
spiral computed tomography. 
However, there is an inflammatory esponse in all pa- 
tients after endoluminal stent graft implantation. With a 
delay of 6 hours after aortic endografting, elevation of 
C-reactive protein (range, 8.4 to 24.8 mg/dl) and leuko- 
cytosis (range, 8.4 to 27.8 x 103/ram 3) developed in all 
patients. Elevated body temperature (range, 38.0 ° to 
39.8 ° C) developed in half of the patients. There was no 
evidence of bacteremia. 2 
Our experimental nd immunologic studies howed a 
significant and uniform elevation ofinterleukin 6, which is 
suspected to be responsible for proinflammatory reaction. 
The graft material acts most likely as a foreign body. This 
reaction is self-limiting, with laboratory findings becoming 
normal within 8 days. 
According to these clinical and experimental data, our 
current policy includes the following regimen for endolu- 
minal repair ofinfrarenal aneurysms: (1) administration of
a single dose of broad-spectrum antibiotics (cephalospo- 






Department of Cardiovascular Surgery 
University of Freiburg 
Hugstetterstr. 55 
Freiburg 79 i06 
Germany 
2. Schlensak C, Weinbeck M, Blum U, Walter S, Spillner G, 
Langer M, BeyersdorfF. Clinica][ experience with transfemoral 
endovascular aortic stent-graft placement for infrarenal aortic 
aneurysm (AAA). Cardiovasc Surg 1996;4(suppl):l. 
24/41/84840 
Reply 
To the Editors: 
We read with interest he letter by Schlensak, Blum, 
Spillner, and Beyersdorf, which refers to their experience 
excluding infrarenal aneurysms 'with the use of a polyester 
textile-covered nitinol stent. In their series of 83 patients, 
they have noted a significant inflammatory response with 
the endoluminal graft implantation but have noted no 
significant infection. We congratulate them for their good 
results in this group of patients. We have noted similar 
findings in our 62 patients who have undergone endolumi- 
nal repair of aortoiliac aneurysms. This inflammatory re- 
sponse has also been noted in our series of 55 patients who 
have undergone placement of an endoluminal graft for 
aortoiliac occlusive disease. We have not observed any 
significant graft infection in any of these patients, either. 
However, these observations are irrelevant to our arti- 
cle. The article in question documents that if an experi- 
mental endovascular p osthesis gets infected, the infection 
is more virulent than after a standard repair. This article 
does not attempt to discuss the incidence of infection after 
endovascular g afting. The world's experience with endo- 
vascular grafts is in its infancy, and the rate of infection is 
still not clear. Our paper merely suggests that if an infec- 
tion develops in an endoluminal graft, the infection is likely 
to be more virulent han that encountered after placement 
of a standard prosthetic arterial graft. 
Luis A. Sanchez, MD 
Division of Vascular Surgery 
Montefiore Medical Center 
111 East 210th St. 
New York, NY 10467-2490 
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Regarding "Stent deformation and intimal 
hyperplasia complicating treatment of  a post-carotid 
endarterectomy intimal flap with a Palmaz stent" 
To the Editors: 
In the article by recently published by Johnson, Fuji- 
tani, Leyendecker, and Joseph (J Vase Surg 1997;25:764- 
8), several questions arise in the endovascular management 
of this particular patient. 
The choice of a JJIS 294 stent in a cervical segment, 
common carotid lesion may not have been the most logical 
choice. In the IDE-sponsored registry for carotid occlusive 
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disease, the JJIS stent is indicated in only bifurcational nd 
internal carotid lesions. The 294 stent was unreasonably 
long in this segment of the carotid artery, which is directly 
exposed to external compression. If for some reason, and I 
cannot imagine why, the JJIS stent was the only option, 
then that stent should have been the much shorter JJIS 
154. After all, the illustrated angiogram demonstrates a 
quite focal lesion, and the short stent would have been 
quite adequate. 
The deformation of the stent that did occur as found 
on the follow-up study appears to be less than 40%. The 
intimal hyperplasia, however, and the restenosis at the 
target site were quite significant and approached at least 
80%. The preliminary data from seven U.S. centers that are 
involved in the carotid stent registry have described stent 
deformation occurring in fewer than 2% of cases and a 
restenosis rate at 6 months of less than 5%. 
The authors' initial decision to use a self-expanding 
flexible Wallstent (Schneider, Minneapolis, Minn.) was 
quite appropriate, realizing that the Wallstent has a flexibil- 
ity feature and is "noncrushable" and would have been 
quite satisfactory for this segment of the carotid artery. 
Discovering, however, that they did not have the ade- 
quate-length stent after they had initiated the procedure 
and were ready for deployment was difficult to explain. The 
procedure should have been terminated at this point. Fur- 
thermore, the authors chose a polyethylene t rephthalate 
balloon for stent deployment with a 0.035 inch wire passed 
across the target lesion and left within the internal carotid 
artery during the deployment process. 
Although the authors discuss the widespread use of 
"off-label applications of endovascular stents," the ques- 
tion occurs whether this particular procedure was per- 
formed under an approved Investigational Device Exemp- 
tion protocol? 
Endovascular stenting for carotid occlusive disease is 
evolving as an alternative to the "gold-standard" ofcarotid 
endarterectomy, but until significant registry data or ran- 
domized controls establish its efficacy and safety, this pro- 
cedure should be confined to experienced centers. 
Mark H. Wholey, MD 
Chairman 
Pittsburgh Vascular Institute 
5230 Centre Ave. 
Pittsburgh, PA 15232 
24/41/85094 
Reply 
To the Editors: 
The authors appreciate Dr. Wholey's comments on our 
article and would like to respond. While we recognize that 
stent technology and deployment techniques are continu- 
ally evolving, it should be noted that this case was per- 
formed in 1994, using techniques considered optimal at 
that time. In addition, we would like to point out that the 
placement of the stent occurred without complication. As 
Roubin et al. stated in their symposium on carotid stenting 
at the Society for Cardiovascular nd Interventional Radi- 
ology's (SCVIR) 22nd Meeting, "the optimal technique 
for carotid stent placement has not been determined," and 
"optimal wire guides, delivery sheaths, balloons, and stents 
have not yet been determined. "1
Dr. Wholey states that he "cannot imagine why a 
Palmaz stent" was the only option. We would like to clarify 
that the reason the Wallstent was not placed was because 
the deployment delivery device was not long enough, not 
because we did not have an adequate-length stent. At the 
time of this procedure, the Wallstent was only available in a 
usable delivery length of 75 cm, which was not long 
enough for adequate deployment from a femoral approach. 
It currently is available in several deployment lengths, in- 
cluding a 135 cm usable delivery system that easily allows 
placement from a femoral approach. Therefore, with the 
possible exception of using a 7F brachial approach, the 
Palmaz stent was the only choice in this patient. The flap 
and intimal irregularity extended over a 1 cm area, and this 
is the reason for the choice of stent length. Furthermore, 
both the 154 and 294 stents are equally prone to deforma- 
tion because they have the same radial hoop strength. 
The point of this case was to illustrate the theoretical 
but previously unpublished concern of placing a deform- 
able stent in the cervical carotid system. Except in the 
situation of a high bifurcation of the carotid artery, the 
distal common carotid artery, bifurcation, and proximal 
internal carotid artery are all located in exposed, potentially 
compressible locations. It should be noted that in Dr. 
Wholey's abstract from this year's SCVIR meeting entitled 
"Endovascular stents for carotid occlusive disease," seven 
of the 58 patients in his subject group who underwent 
carotid stenting had a Palmaz stent placed in the common 
carotid artery. 2
Dr. Wholey cites data on 58 patients from seven cen- 
ters in the carotid stent registry, noting only a 2% deforma- 
tion rate. Other investigators have noted a significantly 
higher rate of Palmaz stent deformation in the carotid 
artery. Vitek et al.,3 who probably have the largest experi- 
ence in the United States, noted a 13% rate ofstent defor- 
mation at 6-month follow-up in the 203 patients they 
treated with balloon-expandable st nts. They concluded 
"because of the risk of stent deformation of balloon-ex- 
pandable stents, it is more appropriate to use the self- 
expandable stents'. 3 
In 1994, this procedure was performed as an off-label 
use of a FDA-approved evice for compassionate reasons. 
The FDA has since clarified clinical research of carotid 
stenting, and we agree with Dr. Wholey that any current 
placements in the United States should be done under 
IRB- and IDE-approved protocols. We are not currently 
performing carotid procedures because we are not satisfied 
